Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luye Pharma Completes US Trials of Anti-Psychotic

publication date: May 15, 2015
Luye Pharma, a China company, has completed three US clinical studies of its investigational version of risperidone, a well-known anti-psychotic drug. Luye encapsulates the active ingredient in microspheres to create an extended release mechanism that requires injections only once every two weeks. Luye expects the three trials, which enrolled a total of 172 patients in the US, will be sufficient for a New Drug filing with the FDA. The drug is also undergoing trials in Europe and Japan. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital